KaliVir Immunotherapeutics
Health Care, Pharmaceutical, Therapeutics
Founded in 1/1/19
Pittsburgh, Pennsylvania, United States
For Profit
About KaliVir Immunotherapeutics
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: None USD
- Last Funding: None (Series A)
- Funding Status: Early Stage Venture
Technology Stack
KaliVir Immunotherapeutics actively uses None products in their tech stack.
Market Presence
Industries: Health Care, Pharmaceutical, Therapeutics
Headquarters: Pittsburgh, Pennsylvania, United States
Employees
- Helena Chaye - Chief Executive Officer (LinkedIn)
- Stephen Thorne - Chief Scientific Officer (LinkedIn)